Smith & Nephew SNATS, Inc. (NYSE:SNN) Receives $36.00 Average Target Price from Analysts

Key Points

• Smith & Nephew SNATS, Inc. (NYSE:SNN) has received an average rating of "Hold" from six research firms, with a consensus price target of $36.00.
• The company announced a semi-annual dividend of $0.285 per share, which reflects a yield of 210.0% and a payout ratio of 41.20%.
• Institutional investors have significantly increased their positions in Smith & Nephew, with notable boosts of up to 6,663.4% from firms like JPMorgan Chase & Co.

Smith & Nephew SNATS, Inc. (NYSE:SNN - Get Free Report) has been assigned a consensus recommendation of "Hold" from the six research firms that are presently covering the stock, MarketBeat.com reports. Six analysts have rated the stock with a hold rating. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $36.00.

SNN has been the subject of several analyst reports. Canaccord Genuity Group upped their price objective on Smith & Nephew SNATS from $28.00 to $36.00 and gave the company a "hold" rating in a research note on Monday, August 18th. Wall Street Zen upgraded shares of Smith & Nephew SNATS from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 30th.

Institutional Trading of Smith & Nephew SNATS

Several large investors have recently modified their holdings of the business. Hexagon Capital Partners LLC increased its position in Smith & Nephew SNATS by 63.3% during the first quarter. Hexagon Capital Partners LLC now owns 1,047 shares of the medical equipment provider's stock worth $30,000 after buying an additional 406 shares in the last quarter. Richards Merrill & Peterson Inc. boosted its holdings in Smith & Nephew SNATS by 500.0% in the first quarter. Richards Merrill & Peterson Inc. now owns 1,200 shares of the medical equipment provider's stock valued at $34,000 after acquiring an additional 1,000 shares during the last quarter. AlphaCore Capital LLC purchased a new stake in shares of Smith & Nephew SNATS during the 2nd quarter worth about $44,000. Bessemer Group Inc. grew its stake in Smith & Nephew SNATS by 3,471.4% during the first quarter. Bessemer Group Inc. now owns 1,750 shares of the medical equipment provider's stock worth $49,000 after buying an additional 1,701 shares during the period. Finally, Banque Transatlantique SA purchased a new stake in Smith & Nephew SNATS during the 1st quarter worth $52,000. 25.64% of the stock is currently owned by institutional investors and hedge funds.

Smith & Nephew SNATS Stock Performance

NYSE:SNN traded down $0.05 during trading hours on Friday, reaching $37.35. 129,821 shares of the company's stock were exchanged, compared to its average volume of 867,809. The firm has a market capitalization of $16.26 billion, a price-to-earnings ratio of 17.30, a P/E/G ratio of 1.03 and a beta of 0.71. The company has a 50-day moving average of $34.67 and a 200 day moving average of $30.58. The company has a quick ratio of 1.40, a current ratio of 3.00 and a debt-to-equity ratio of 0.60. Smith & Nephew SNATS has a 1-year low of $23.69 and a 1-year high of $38.79.

Smith & Nephew SNATS Cuts Dividend

The company also recently announced a semi-annual dividend, which will be paid on Friday, November 7th. Shareholders of record on Friday, October 3rd will be given a dividend of $0.285 per share. This represents a yield of 210.0%. The ex-dividend date is Friday, October 3rd. Smith & Nephew SNATS's payout ratio is presently 41.20%.

About Smith & Nephew SNATS

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.